10-Q: Pulse Biosciences Reports Q3 2025 Loss Amid R&D Surge

Pulse Biosciences reported increased net losses in Q3 2025 as it ramps up R&D and commercialization efforts for its NPS technology, securing first product revenue.

Summary

• Net loss for the nine months ended September 30, 2025, increased to $55.3 million from $34.2 million in the same period of 2024.
• Product revenue for the nine months ended September 30, 2025, was $86,000, marking the company's first commercial sales of the Vybrance Percutaneous Electrode System.
• Research and development expenses surged by $12.1 million to $33.8 million for the nine months ended September 30, 2025, primarily due to increased paid services, external research, stock-based compensation, and employee-related expenses.
• Selling, general and administrative expenses rose by $10.4 million to $24.7 million for the nine months ended September 30, 2025, driven by higher stock-based compensation, employee-related expenses, and promotional costs.
• Cash and cash equivalents decreased by $22.8 million to $95.2 million as of September 30, 2025, from $118.0 million at December 31, 2024.
• Net cash used in operating activities increased to $39.4 million for the nine months ended September 30, 2025, compared to $27.2 million in the prior year period.
• The company believes its existing cash and cash equivalents are sufficient to fund projected operating requirements for at least the next twelve months.
• Stockholders approved an amendment to the 2017 Equity Incentive Plan on September 30, 2025, increasing shares reserved for issuance by 2,000,000.

Sentiment

Score: 4

Explanation: The company shows significant progress in clinical development and regulatory milestones for its core technologies, including first product revenue and FDA Breakthrough Device Designation. However, this progress comes with a substantial increase in net losses and cash burn, reflecting the high investment phase of a development-stage medical technology company. The reliance on future capital raises and the competitive landscape temper the overall sentiment.

Positives

• Achieved first product revenue of $86,000 for the nine months ended September 30, 2025, from the limited market release of the Vybrance Percutaneous Electrode System.
• Received FDA 510(k) clearance for the Vybrance Percutaneous Electrode System in March 2024 and for a second needle size in August 2024.
• Initiated a pivotal clinical trial for the nPulse Cardiac Surgical Clamp for atrial fibrillation (AF) with the first patient treated, following IDE approval.
• Received Breakthrough Device Designation from the FDA for the nPulse Cardiac Surgery System for AF in July 2024.
• The Cardiac Surgery System was enrolled in the FDA's Total Product Life Cycle (TPLC) Advisory Program (TAP), designed to expedite development and review.
• Encouraging acute and remapping data from clinical studies of the nPulse 360 Cardiac Catheter in Prague and Rome, with 150 patients treated to date.
• Interest income increased by $1.6 million to $3.4 million for the nine months ended September 30, 2025, driven by higher cash balances.

Negatives

• Net loss significantly increased to $55.3 million for the nine months ended September 30, 2025, compared to $34.2 million in the prior year.
• Operating expenses, including R&D and SG&A, increased substantially, contributing to the higher net loss.
• Net cash used in operating activities increased to $39.4 million, indicating a higher cash burn rate.
• Net cash provided by financing activities decreased significantly to $16.8 million for the nine months ended September 30, 2025, compared to $61.9 million in the prior year, primarily due to the absence of a large rights offering in 2025.
• The company has incurred substantial operating losses since inception and expects to continue incurring losses for at least the next several years.
• The exact mechanism of action of NPS technology is not fully understood, which could challenge regulatory approvals or partnerships.

Risks

• The company will need to obtain additional funding to finance operations and complete product development and commercialization, with no assurance of availability on acceptable terms.
• Heavy dependence on the success of Nano-pulse Stimulation (NPS) technology; failure or delays could extend significant financial losses.
• Limited experience commercializing products and anticipates continued losses for several years, with no guarantee of future profitability.
• Future capital raises may result in further dilution to investors or incur indebtedness, potentially impairing liquidity.
• Medical device development and commercialization is a complex, time-consuming, expensive process with a high rate of failure.
• No assurance that clinical product candidates, including those for atrial fibrillation, will obtain regulatory approval or that clinical study results will be favorable.
• Limited sales and marketing experience, and no assurance that devices will be adopted by surgeons or other physicians.
• Regulatory requirements and timelines may cause significant delays to product launches.
• Intense competition from large, well-established medical technology manufacturers with greater resources.
• Commercialization could be delayed or prevented by unforeseen events in clinical trials.
• Failure of clinical trials to demonstrate safety and effectiveness could lead to additional costs or inability to complete development.
• Reliance on a single family of products (nPulse System) and platform technology (NPS) makes the company vulnerable to market acceptance issues or technological obsolescence.
• Inability to manage anticipated business growth could harm future revenue and operating results.
• Potential manufacturing problems or delays, and reliance on third-party suppliers for critical components, could interrupt supply and delay product development.
• Commercial viability depends on obtaining adequate reimbursement by Medicare and other third-party payers, which is not assured and can be a lengthy, costly process.
• Ability to utilize net operating loss carryforwards and other tax attributes may be limited by ownership changes.
• Substantial goodwill and intangible assets may be subject to future write-downs if impairment is identified.
• Products may cause serious adverse side effects, delaying regulatory approval, limiting commercial desirability, or resulting in negative consequences.
• Interim clinical trial results may change as more data become available and are subject to audit and verification.
• Issues with firmware and software may negatively affect device function or lead to security breaches.
• Inability to protect intellectual property could adversely affect financial condition and the value of technology and products.
• Actual or perceived failure to comply with data privacy and security obligations could lead to regulatory actions, litigation, fines, and business disruptions.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Subject to stringent domestic and foreign regulation; unfavorable regulatory action or adverse changes in law could harm the business.
• Changes in healthcare policy could increase costs, decrease revenue, and impact sales and reimbursement.
• Disruptions in the FDA and other government agencies due to funding shortages or global health concerns could hinder product development and commercialization.
• Dependence on maintaining strong working relationships with physicians, which are under increasing scrutiny by government agencies.
• Exposure to the risk of fraud or other misconduct by employees and independent contractors, including noncompliance with regulatory standards and insider trading.
• Subject to environmental regulations; failure to comply could lead to significant liabilities.
• Potential negative impact from actual or perceived violations of anti-corruption laws.
• The price of common stock has been, and is expected to continue to be, highly volatile.
• Sales or purchases of common stock by the company or its stockholders, particularly the majority stockholder, may adversely affect the market price.
• Concentration of ownership by the principal stockholder (Robert W. Duggan, ~72%) limits the ability of others to influence corporate actions and creates potential for conflicts of interest.
• Operating as a public company incurs significant costs and requires substantial management time for compliance initiatives.
• As a smaller reporting company, reduced disclosure requirements may make common stock less attractive to investors.
• No plans to pay dividends in the foreseeable future.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Unfavorable global economic or political conditions could adversely affect the business.
• Risk of material weaknesses in internal control over financial reporting in the future.
• Incorrect interpretations, estimates, or judgments in financial statements could cause stock price decline.
• Involvement in litigation could materially adversely affect the company.
• Facilities in California are located near known earthquake faults, posing a risk of damage and operational disruption.

Future Outlook

The company expects to continue incurring significant operating losses for the next several years as it invests in research and development and commercialization efforts. It plans to pursue more clinical evidence-based milestones throughout 2025 for its percutaneous electrodes and expects to complete enrollment for the PRECISE BTN clinical trial in Q1 2026. The pivotal clinical study for the nPulse 360 Cardiac Catheter is expected to commence in Q1 2026, pending resolution of remaining FDA open items. The company believes existing cash will fund operations for at least the next twelve months but plans to raise additional capital in the future, potentially through equity offerings, debt financings, or collaborations.

Management Comments

• We believe our existing cash and cash equivalents will be sufficient to fund our projected operating requirements for at least the next twelve months from the filing date of this Quarterly Report on Form 10-Q.
• We plan to raise additional capital in the future.
• We expect to pursue more clinical evidenced-based milestones throughout 2025 in connection with evaluating the limited market release of our percutaneous electrodes.
• We expect to complete enrollment in Q1 2026 for the PRECISE BTN clinical trial.
• We expect to resolve several remaining open items over the next couple of months and will be in position to commence the pivotal clinical study for the nPulse 360 Cardiac Catheter in Q1 2026.
• We continue to believe we will need PMA approval from the FDA in order to market and sell our catheter in the United States.

Industry Context

Pulse Biosciences operates in the highly competitive and rapidly evolving medical technology industry, specifically focusing on ablation technologies. Its shift from dermatology to cardiology and soft tissue ablation positions it in markets with significant unmet needs, such as atrial fibrillation (AF) and benign thyroid nodules. The company's Nano-pulse Stimulation (NPS) technology, particularly Nanosecond Pulsed-Field Ablation (nsPFA), aims to differentiate itself from traditional thermal ablation methods by offering nonthermal, precise cellular tissue removal with potential safety advantages (sparing acellular tissue like collagen and nerves). The FDA's Breakthrough Device Designation and TAP enrollment for its cardiac system highlight the potential for nsPFA to significantly improve patient outcomes in AF, a condition affecting 43 million people worldwide. However, the industry is dominated by large players like Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic, many of whom are also developing Pulsed Field Ablation (PFA) products, posing substantial competition.

Comparison to Industry Standards

• The nPulse Cardiac Clamp has consistently achieved transmural ablations in preclinical studies in less than two seconds, independent of tissue type or thickness, which is presented as faster than thermal modalities.
• nsPFA ablation's nonthermal mechanism is highlighted as potentially superior to thermal modalities by avoiding char formation and not being affected by heatsinks like blood, which can cause gaps in ablation lines and treatment failure in competitors' products.
• The technology's ability to spare acellular tissue (collagen, cartilage) and nerves from permanent damage is presented as a significant safety advantage over thermal modalities used by competitors when ablating near vessels and valves.
• The nPulse 360 Cardiac Catheter's circumferential ablation design in a single treatment cycle is positioned as enabling faster treatment times compared to current thermal modalities, especially around pulmonary veins, a common AF treatment approach.
• While other PFA technologies (micro-PFA) exist in AF treatment, nsPFA is presented as potentially offering improved efficacy due to its shorter pulse widths and ability to create deeper ablations.

Management Changes

Corporate Governance

Legal Proceedings

• Not presently a party to any legal proceedings that, in management's opinion, could have a material adverse effect on results of operations or financial condition.
• Acknowledges that any litigation, regardless of outcome, could have an adverse impact due to defense and settlement costs, diversion of management resources, negative publicity, and reputational harm.

Related Party Transactions

• Robert W. Duggan, the company's majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the 2024 Rights Offering, which generated $60 million in gross proceeds.
• Mr. Duggan beneficially owns approximately 72% of the company's common stock outstanding, giving him control over corporate actions requiring stockholder approval.
• Three directors, including Mr. Duggan and Manmeet Soni (Lead Independent Director and Audit Committee Chairman), are executives at Summit Therapeutics Inc., another company in which Mr. Duggan holds a controlling equity interest, creating potential for conflicts of interest.
• The company engaged outside legal counsel who also represents Mr. Duggan personally in other matters, and this counsel represented Mr. Duggan in certain related party transactions and could do so in future transactions.
• Mr. Duggan and Dr. Zanganeh (married) together hold over 74% beneficial ownership.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution from future capital raises. Stock price volatility and limited influence on corporate governance due to majority ownership by Robert W. Duggan. Potential for substantial losses if products fail or additional funding is not secured. However, clinical progress and regulatory designations could drive long-term value.
• **Employees:** Increased stock-based compensation expenses indicate continued incentive programs. Headcount reductions are a risk if funding is insufficient. Future success depends on retaining key personnel and attracting skilled professionals.
• **Customers (Physicians/Medical Clinics):** Introduction of new Vybrance Percutaneous Electrode System and cardiac ablation devices offers new treatment options. Adoption depends on training, reimbursement, and demonstrated safety/effectiveness. Initial evaluation programs are underway.
• **Suppliers:** Reliance on third-party suppliers for critical components means any issues could delay product development and commercialization.
• **Creditors:** Increased operating losses and cash burn could impact the company's ability to service future debt, although current cash is deemed sufficient for 12 months.

Next Steps

• Pursue more clinical evidence-based milestones throughout 2025 for the Vybrance Percutaneous Electrode System.
• Complete enrollment for the PRECISE BTN clinical trial in Q1 2026.
• Resolve remaining open items with the FDA for the nPulse 360 Cardiac Catheter IDE submission.
• Commence the pivotal clinical study for the nPulse 360 Cardiac Catheter in Q1 2026.
• Seek PMA approval from the FDA to market and sell the nPulse Cardiac Surgical System and nPulse 360 Cardiac Catheter in the United States.
• Continue to improve operational, financial, and management controls to support anticipated business growth.
• Evaluate the impact of new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-05) on consolidated financial statements and disclosures.

Key Dates

Recommendation

Pulse Biosciences is in a critical, high-investment phase, marked by significant R&D and commercialization efforts for its innovative Nano-pulse Stimulation technology. While the company has achieved notable operational milestones, including first product revenue, FDA clearances, and Breakthrough Device Designation for its cardiac system, these advancements are accompanied by substantially increased net losses and cash burn. The company's liquidity is currently sufficient for the next 12 months, but future capital raises are anticipated, which could lead to further shareholder dilution. The concentrated ownership by Robert W. Duggan presents both a potential source of funding and a governance consideration. Given the early stage of commercialization, the inherent risks of medical device development, intense competition, and the need for future financing, a 'hold' recommendation is appropriate. Investors should monitor clinical trial outcomes, regulatory approvals, commercial adoption rates, and future financing activities closely, as these will be key determinants of long-term value.

Keywords

Nano-pulse Stimulation, nsPFA, Atrial Fibrillation, Cardiac Ablation, Soft Tissue Ablation, Vybrance Percutaneous Electrode System, nPulse System, Medical Device, Biotechnology, FDA Clearance, Clinical Trials, Q3 2025 Earnings, SEC Filing, PLSE